Bio-Techne Corp continues to enhance its portfolio with a series of movements including collaborations, acquisitions, and strategic investments.
Thermo Fisher Scientific distribution agreement and key participations in investor healthcare conferences signify progression.
Corporate Sustainability Report 2024 and appointment of a new member, Dr. Judith Klimovsky, into the board of directors underscore commitment to growth and environmental sustainability. An investment in
Wilson Wolf and partnerships with
Cell Signaling Technology,
Discovery Life Sciences, and
Asuragen highlight its bet in the future of its technology. Declarations of dividends and a stock split prove the company is profitable but it still underperforms the healthcare market sector. Bio-Techne was a part of the
best biotech stocks list for October 2024, but missed Q4 2024 earnings per share predictions. Series of
G-REx® grants have been accorded by
ScaleReady to support advanced research in cell, gene therapies and the biotech industry. Recent
patent infringement lawsuit filed against Molecular Instruments points to IP protection vigilance.
Bio-Techne Corp TECH News Analytics from Sun, 13 Jul 2014 07:00:00 GMT to Sat, 12 Oct 2024 09:02:19 GMT -
Rating 2
- Innovation 4
- Information 6
- Rumor -8
